,Date,Title,URL,Journal,Severe,Severe lower bound,Severe upper bound,Severe p-value,Severe Significant,Severe Adjusted,Severe Calculated,Fatality,Fatality lower bound,Fatality upper bound,Fatality p-value,Fatality Significant,Fatality Adjusted,Fatality Calculated,Multivariate adjustment,Design,Sample,Study population,Added on,Critical only,Discharged vs. death?,Sample Text,Matches,Entry
,2020-05-31,Liver injury in COVID-19: management and challenges,https://doi.org/10.1016/s2468-1253(20)30057-1,The Lancet Gastroenterology & Hepatology,,,,,,,,,,,,,,,,Other,1099,"1, In this Comment, we assess how the liver is affected using the available case studies and data from The Fifth Medical Center of PLS General Hospital, Beijing, China.",,,,"Moreover, in a large cohort including 1099 patients from 552 hospitals in 31 provinces or provincial municipalities, more severe patients with disease had abnormal liver aminotransferase levels than did non-severe patients with disease.","Liver diseases including chronic viral hepatitis, non-alcoholic fatty liver disease, and alcohol-related liver disease affect approximately 300 million people in China.",2020-04-17
,2020-05-08,Clinical characteristics of Coronavirus Disease (COVID-19) patients with gastrointestinal symptoms: A report of 164 cases,https://doi.org/10.1016/j.dld.2020.04.034,Digestive and Liver Disease,,,,,,,,,,,,,,,,Case series,504,"Clinical data were extracted from the electronic medical records of 504 patients with confirmed COVID-19 patients who were treated at the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology and retrospectively analysed.",,,,"Clinical data were extracted from the electronic medical records of 504 patients with confirmed COVID-19 patients who were treated at the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology and retrospectively analysed.","Comorbidities included chronic lung disease, hypertension, coronary heart disease, diabetes, chronic kidney disease, chronic liver disease (including cirrhosis), cerebrovascular disease, and malignancy.",2020-05-12
,2020-05-06,A WEB-BASED GROUP TREATMENT FOR PATIENTS WITH ALCOHOLIC LIVER DISEASES AT THE TIME OF THE COVID-19 PANDEMIC,https://doi.org/10.1016/j.dld.2020.04.023,Digestive and Liver Disease,,,,,,,,,,,,,,,,Other,10,"Ten ALD patients (mean age 44.5 ± 5.0; 40% male) were included from March 11th, 2020.",,,,"Ten ALD patients (mean age 44.5 ± 5.0; 40% male) were included from March 11th, 2020.",Alcohol-related liver diseases (ALD) are the most frequent hepatic diseases and the main cause of liver disease-related death and liver transplantation .,2020-05-12
,2020-04-28,The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196920/,Expert Rev Respir Med,,,,,,,,,,,,,,,,Retrospective observational,212,Methods: All consecutive patients diagnosed with COVID-19 admitted to the Zhongnan Hospital of Wuhan University from 11 January to 16 March 2020 were enrolled in this retrospective cohort study.,,,,Results: A total of 212 COVID-19 patients were included.," Heart, liver, and kidney comorbidities were common in COVID-19 patients.

The proportion of cardiovascular diseases, liver diseases, kidney diseases, and ≥2 comorbidities were 15.6%(33/212), 10.8%(23/212), 5.2%(11/212), and 10.4%(22/212), respectively.",2020-05-12
,2020-04-25,COVID-19 Fatality and Comorbidity Risk Factors among Confirmed Patients in Mexico,https://doi.org/10.1101/2020.04.21.20074591,medrxiv,,,,,,,,,,,,,,,,Other,7497,"In this paper we estimate fatality risks based on survival analysis methods, calculated from individual-level data on symptomatic patients confirmed with COVID-19 recently released by the Mexican Ministry of Health.",,,,"Our analysis is based on 7,497 patients who tested positive for COVID-19 in Mexico, a subset of a larger dataset of 49,167 patients with COVID-19 related symptoms who sought attention in medical units and were tested with positive, negative (29,301 cases) and pending (12,369 cases) results.","In contrast, high blood pressure increases the estimated hazard by 38% (HR=1.378, 95% CI: 1.086-1.749), immune suppression by 70% (HR=1.696, 95% CI: 1.148-2.505), diabetes by 73% (HR=1.730, 95% CI: 36.0-120.2), COPD by 77% (HR=1.770, 95% CI: 1.269-2.469), obesity by 78% (HR=1.776, 95% CI: 1.415-2.231), and chronic liver disease by 168% (HR=2.679, 95% CI: 1.789-4.014).",2020-05-01
,2020-04-22,Coronavirus Disease (COVID-19) Pandemic: An Overview of Systematic Reviews,https://doi.org/10.1101/2020.04.16.20068213,medrxiv,,,,,,,,,,,,,,,,Systematic review,1063,"Methods: Nine databases (Medline, EMBASE, Cochrane Library, CINAHL, Web of Sciences, PDQ-Evidence, WHO's Global Research, LILACS and Epistemonikos) were searched from December 1, 2019 to March 24, 2020.",,,,"Our search retrieved 1,063 publications, of which 175 were duplicates.","There was a higher likelihood that patients with severe disease had hypertension (OR 2.36, 95% CI: 1.46-3.83), respiratory disease (OR 2.46, 95% CI: 1.76-3.44), or cardiovascular disease (OR 3.42, 95% CI: 1.88-6.22), compared with patients with non-severe disease.

The most common comorbidities were hypertension (17±7, 95% CI 14-22%), diabetes (8±6, 95% CI 6-11%), cardiovascular diseases (5±4, 95% CI 4-7%) and respiratory system diseases (2±0, 95% CI 1-3%).",2020-05-01
,2020-04-21,Gastrointestinal and liver manifestations in patients with COVID-19,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176263/,J Chin Med Assoc,,,,,,,,,,,,,,,,Other,1099,"Pan et al17 described the clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China.",,,,"In the currently largest cohort including 1099 patients with laboratory-confirmed COVID-19 from 552 hospitals in 30 provinces in China through January 29, 2020, nausea or vomiting and diarrhea were reported in 55 (5%) and 42 (3.8%) patients, respectively.","The impact of COVID-19 in patients with preexisting chronic liver diseases, such as viral hepatitis, nonalcoholic fatty liver disease, and alcohol-related liver disease, remains to be evaluated.

34 The impact of COVID-19 in patients with preexisting chronic liver diseases, such as viral hepatitis, nonalcoholic fatty liver disease, and alcohol-related liver disease, remains to be evaluated.",2020-05-01
,2020-04-16,Cardiovascular Diseases and COVID-19 Mortality and Intensive Care Unit Admission: A Systematic Review and Meta-analysis,https://doi.org/10.1101/2020.04.12.20062869,medrxiv,,,,,,,,,,,,,,,,Systematic review,3473,"Searched Databases included PubMed, Embase, Scopus, Web of Science, Cochrane Library, medRxiv pre-print database as well as Science Direct search engine.",,,,Results: Sixteen papers including 3473 patients entered into meta-analysis for ICU admission and mortality outcome and fifty-nine papers including 9509 patients for descriptive outcomes.,"Results of meta-analysis indicated that acute cardiac injury, (OR: 15.94, 95% CI 2.31-110.14), hypertension (OR: 1.92, 95% CI 1.92-2.74), heart Failure (OR: 11.73, 95% CI 5.17-26.60), other cardiovascular disease (OR: 1.95, 95% CI 1.17-3.24) and overall CVDs (OR: 3.37, 95% CI 2.06-5.52) were significantly associated with mortality in COVID-19 patients.

Results of meta-analysis indicated that acute cardiac injury (OR: 15.94, 95% CI 2.31-110.14), Hypertension (OR: 1.92, 95% CI 1.92-2.74), Heart Failure (OR: 11.73, 95% CI 5.17-26.60), other cardiovascular disease (OR: 1.95, 95% CI 1.17-3.24) and overall CVDs (OR: 3.37, 95% CI 2.06-5.52) were significantly associated with mortality in COVID-19 patients.",2020-04-24
,2020-04-13,COVID-19: Abnormal liver function tests,https://doi.org/10.1016/j.jhep.2020.04.006,Journal of Hepatology,,,,,,,,,,,,,,,,Cross-sectional,417,"Methods Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020.",,,,"Methods Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020.","Sensitivity analyses excluding 21 patients with preexisting liver disease showed similar results, with the adjusted ORs (95% CIs) for severity being 1.73 (0.94-3.16) and 1.86 (0.58-5.92) in patients with abnormal liver tests and liver injury, respectively (Table not shown) .

After similar adjustment, patients with liver injury were at a 9-fold greater risk of severe COVID-19 ( patients with abnormal liver tests and liver injury during hospitalization, respectively (Table not shown) .

Patients also tended to have underlying liver diseases, including NAFLD, alcoholic liver disease, and chronic hepatitis B (p = 0.001), and had cough as an initial symptom (p = 0.04) ( Table 1) .

Patients with abnormal liver tests of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios [ORs] 2.73; 95% CI 1.19–6.3, and 4.44, 95% CI 1.93–10.23, respectively).",2020-05-12
,2020-04-08,A model to predict SARS-CoV-2 infection based on the first three-month surveillance data in Brazil.,https://doi.org/10.1101/2020.04.05.20047944,medrxiv,,,,,,,,,,,,,,,,Case series,1468,We included the patients reported between 11/01/2020 and 25/03/2020.,,,,Results: We described 1468 COVID-19 cases (confirmed by RT-PCR) and 4271 patients with other illnesses.,Variable Kidney disease OR (95% CI) 0.06 (0 - 1.06) p value 0.06,2020-04-17
,2020-03-30,"Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis",https://doi.org/10.1101/2020.03.25.20043133,medrxiv,,,,,,,,,,,,,,,,Systematic review,182,"Methods Available data from PubMed, Web of Science, China National Knowledge Infrastructure Database, WanFang Database and VIP Database, were analyzed using a fixed effects model meta-analysis to derive overall odds ratios (OR) with 95% CIs.",,,,"182 studies were retrieved, and 9 studies were finally included after selection.","There were significant correlations between COVID-19 severity and hypertension [OR=2.3 [95% CI (1.76, 3.00), P<0.01], diabetes [OR=2.67, 95% CI (1.91, 3.74), P<0.01], coronary heart disease [OR=2.85 [95% CI (1.68, 4.84), P<0.01].",2020-04-03
,2020-03-30,Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132021/,J Clin Transl Hepatol,,,,,,,,,,,,,,,,Other,1099,"9 extracted data regarding 1099 patients with laboratory-confirmed COVID-19 from 552 hospitals in mainland China through January 29, 2020.",,,,"9 extracted data regarding 1099 patients with laboratory-confirmed COVID-19 from 552 hospitals in mainland China through January 29, 2020.","In addition, given the high burden of chronic liver disease in China, nonalcoholic fatty liver disease, chronic hepatitis B, and liver cirrhosis might be the major alternative causes of liver injury in Chinese patients with COVID-19.",2020-04-17
,2020-03-26,"COVID-19 clinical characteristics, and sex-specific risk of mortality: Systematic Review and Meta-analysis",https://doi.org/10.1101/2020.03.24.20042903,medrxiv,,,,,,,,,,,,,,,,Systematic review,4789,"Methods: We reviewed the scientific literature published from January 1, 2019 to March 3, 2020.",,,,A total of 4789 patients with a mean age of 49 years were evaluated.,"The most common comorbidities were respectively hypertension (18.5 %, CI 12.7-24.4), 246 cardiovascular diseases (14.9 %, CI 6.0-23.8), diabetes (10.8 %, CI 8.3-13.3), chronic liver 247 disease (8.1, CI 4.6-11.6) and smoking (8.0%, CI 2.3-13.6) ( Table 3) .

Acute kidney injury was found in 5.5% (CI 1.3-20.8).",2020-04-03
,2020-03-20,"Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis",https://doi.org/10.1101/2020.03.17.20037572,medrxiv,,,,,,,,,,,,,,,,Systematic review,30,"Methods: The PubMed, Web of Science Core Collection, Embase, Cochrane and MedRxiv databases were searched through February 25, 2020.",,,,"Results: A total of 30 studies including 53000 patients with COVID-19 were included in this study, the mean age was 49.8 years (95% CI, 47.5-52.2 yrs) and 55.5% were male.","Comorbidities with pooled OR larger than 2 included CKD (6.02; 95% CI, 2.19-16.51; n = 4; I 2 = 0), COPD (5.32; 95% CI, ; n = 6; I 2 = 0%), cerebrovascular diseases (3.19 ; 95% CI, 1.51-6.77; n = 6; I 2 = 0%), tumor (3.21; 95% CI, ; n = 4; I 2 = 30%), diabetes (2.49; 95% CI, ; n = 10; I 2 = 44%) and hypertension (2.06; 95% CI, 1.61-2.62; n = 10; I 2 = 36%) ( Figure 4 , eFigure 5).

The predictor for disease severity included old age (≥ 50 yrs, odds ratio [OR] = 2.61; 95% CI, 2.29-2.98), male (OR =1.348, 95% CI, 1.195-1.521), smoking (OR =1.734, 95% CI, 1.146-2.626) and any comorbidity (OR = 2.635, 95% CI, 2.098-3.309), especially chronic kidney disease (CKD, OR = 6.017; 95% CI, 2.192-16.514), chronic obstructive pulmonary disease (COPD, OR = 5.323; 95% CI, 2.613-10.847) and cerebrovascular disease (OR = 3.219; 95% CI, 1.486-6.972).",2020-03-27
,2020-03-12,Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis,https://doi.org/10.1016/j.ijid.2020.03.017,Int J Infect Dis,,,,,,,,,,,,,,,,Systematic review,576,"A systematic search was conducted on studies published from January 1, 2019 to February 25, 2020 in PubMed, EMBASE, and Web of Science databases.",,,,"As of February 25, 2020, a total of 1 576 participants were included in our meta-analysis.","Higher risk of hypertension (OR 2.36, 95% CI: 1.46–3.83), respiratory system disease (OR 2.46, 95% CI: 1.76–3.44), and cardiovascular disease (OR 3.42, 95% CI: 1.88–6.22) were observed in the severe group.

Higher risk of hypertension (OR 2.36, 95% CI: 1.46-3.83), respiratory system disease (OR 2.46, 95% CI: 1.76-3.44), and cardiovascular disease (OR 3.42, 95% CI: 1.88-6.22) were observed in the severe group.

The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0–27.2%) and diabetes (9.7%, 95% CI: 7.2–12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8–13.8%) and respiratory system disease (1.5%, 95% CI: 0.9–2.1%).

When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46–3.83), 2.46 (95% CI: 1.76–3.44) and 3.42 (95% CI: 1.88–6.22) respectively.",2020-05-12
,2020-02-28,Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease,https://doi.org/10.1097/cm9.0000000000000775,Chin Med J (Engl),,,,,,,,,,,,,,,,Other,11,"Patients included in the study had been diagnosed with COVID-19 associated pneumonia between December 30, 2019, and January 15, 2020 , and hospitalized at one of three tertiary hospitals in Wuhan for over two weeks.",,,,"A total of 11 patients (14.1%) were included in the progression group, and 67 patients (85.9%) were included in the improvement/stabilization group.","The results of univariate logistic analysis found that age (OR, 10.575; 95% CI: 2.095–53.386; P = 0.004), history of smoking (OR, 12.187; 95% CI: 1.762–84.306; P = 0.011), maximum body temperature at admission (OR, 9.709; 95% CI: 1.176–83.330; P = 0.035), respiratory failure (OR, 8.021; 95% CI: 2.022–31.821; P = 0.003), severe illness (OR, 4.651; 95% CI: 0.930–23.250; P = 0.061), albumin (OR, 12.536; 95% CI: 2.409–65.233; P = 0.003), creatinine (OR, 6.800; 95% CI: 1.424–32.470; P = 0.016), procalcitonin (OR, 3.831; 95% CI: 0.551–27.027; P = 0.071), C-reactive protein (OR, 5.988; 95% CI: 1.179–30.300; P = 0.031) were significantly associated with the disease progression.",2020-05-12
0,2020-04-29,"Role of Drugs Affecting the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity of COVID-19: A Large Case-Control Study from Zheijang Province, China.",https://doi.org/10.1101/2020.04.24.20077875,medrxiv,AOR: 0.83,0.32,2.18,0.71,Not Significant,Adjusted,Extracted,,,,,,,,,Retrospective observational study,610,"14 hospitals in Zhejiang province, China between Jan 10 and Feb 28, 2020 and confirmed diagnosis of Covid-19 infection were included",5/6/2020,N,N,,,
1,2020-04-25,The role of comorbidities and clinical predictors of severe disease in COVID-19: a systematic review and meta-analysis Emails,http://doi.org/10.1101/2020.04.21.20074633,,OR 1.25,0.35,4.41,,Not Significant,Not Adjusted,Extracted,,,,,,,,,Systematic review and meta-analysis,6 studies,"PubMed, Scopus, EMBASE, Web of Science, and Google Scholar searched through March 12 2026",5/6/2020,Y,N,,,
2,2020-04-03,"Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020 [MMWR Morb Mortal Wkly Rep]",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119513/,Morbidity and Mortality Weekly Report,OR 3.49,1.54,7.91,<0.01,Significant,Not Adjusted,Calculated,,,,,,,,,Retrospective observational study,7162,"CDC passive surveillance registry as of March 28, 2021",5/6/2020,Y,N,,,
3,2020-03-23,Prognostic value of C-reactive protein in patients with COVID-19,https://doi.org/10.1101/2020.03.21.20040360,medRxiv,,,,,,,,OR: 1.17,0.39,3.47,0.78,Not Significant,Not Adjusted,Calculated,,Retrospective observational study,298,"Eastern Campus of Renmin Hospital of Wuhan University from Jan 30 to Feb 20, 2028",4/10/2020,N,Y,,,
4,2020-02-23,ACP risk grade: a simple mortality index for patients with confirmed or suspected severe acute respiratory syndrome coronavirus 2 disease (COVID-19) during the early stage of outbreak in Wuhan China,https://doi.org/10.1101/2020.02.20.20025510,medRxiv,OR 0.56,0.21,1.53,0.26,Not Significant,Not Adjusted,Calculated,,,,,,,,,Retrospective observational study,577,"Wuhan Hankou Hospital from Jan 21 to Feb 5, 2020",5/6/2020,N,N,,,
